JAMA
AHA 2025: Daily caffeine linked to lower afib recurrence
Moderate daily coffee intake may offer protective effects against afib recurrence. Presented at the American Heart Association (AHA) Scientific Sessions, the study adds weight to reconsidering caffeine restrictions in afib management, though individualized guidance and further research remain warranted.
Study details: The randomized DECAF trial (NCT05121519) enrolled 200 adults (mean age, 69; 71% male) with persistent afib or atrial flutter following successful cardioversion. Participants were randomized to either consume at least one cup of caffeinated coffee daily or abstain from all caffeine for six months. Primary endpoint was clinically detected recurrence of afib or atrial flutter over the follow-up period.
Results: Coffee intake averaged 7 cups/week in the consumption group vs. 0 cups/week in the abstinence group. Afib or atrial flutter recurred in 47% of the coffee group vs. 64% of the abstinence group, corresponding to a 39% lower risk of recurrence (hazard ratio, 0.61; 95% confidence interval, 0.42–0.89; P=.01) with coffee consumption. No significant differences in adverse events were observed between groups.
Source:
Wong CX, et al. (2025, November 9). JAMA. Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation: The DECAF Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/41206802/